Brochure | December 4, 2014

High Throughput Screening Of Novel Protein Therapeutics

Source: INTEGRA Biosciences
To access this content, please Register or Sign In.
ibspr172-imageB

Integrating an INTEGRA VIAFLO 96 multichannel pipette into their high throughput expression facility has enabled Molecular Partners (Zurich, Switzerland) to streamline the discovery and development of a novel class of targeted protein therapeutics termed DARPins.

DARPins are a next generation of protein therapeutics combining the advantages of antibodies and small molecule drugs. High target specificity and potency, small size, cost-effective production and a whole range of possible multi-specific format choices gives them the potential to surpass existing antibody drugs and revolutionize protein therapeutics.

Andreas Lehmann, an Expert Technical Assistant working in Molecular Partners 96-well high throughput expression facility commented...